State Street’s Lexeo Therapeutics LXEO Stock Holding History

State Street’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3M	Buy	4,354,757 +786,515	+22%	+$4.25M	﹤0.01%	2350
2026 Q1	$20.5M	Buy	3,568,242 +380,520	+12%	+$2.7M	﹤0.01%	2224
2025 Q4	$31.7M	Buy	3,187,722 +2,642,877	+485%	+$24.1M	﹤0.01%	2004
2025 Q3	$3.62M	Buy	544,845 +31,819	+6%	+$154K	﹤0.01%	3123
2025 Q2	$2.06M	Buy	513,026 +43,298	+9%	+$142K	﹤0.01%	3305
2025 Q1	$1.63M	Buy	469,728 +12,325	+3%	+$54.6K	﹤0.01%	3315
2024 Q4	$3.01M	Buy	457,403 +203,457	+80%	+$1.6M	﹤0.01%	3175
2024 Q3	$2.3M	Buy	253,946 +57,674	+29%	+$688K	﹤0.01%	3280
2024 Q2	$3.15M	Buy	196,272 +84,057	+75%	+$1.22M	﹤0.01%	3123
2024 Q1	$1.76M	Buy	+112,215	New	+$1.75M	﹤0.01%	3321

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street's LXEO Position: Q2 2026 in Review

State Street increased its Lexeo Therapeutics (LXEO) stake by 22% in Q2 2026, buying an estimated $4.25M and bringing the position to 4,354,757 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2350.

State Street first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $31.7M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

State Street held 4,354,757 shares of Lexeo Therapeutics worth $20.3M as of Q2 2026.
State Street bought 786,515 Lexeo Therapeutics shares in Q2 2026, an estimated $4.25M.
Lexeo Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2350 holding.
State Street first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
State Street's Lexeo Therapeutics position peaked at $31.7M in Q4 2025.
141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.